within Pharmacolibrary.Drugs.ATC.D;

model D06BB06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 9.550000000000002e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00108,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00117,
    k12             = 4.26,
    k21             = 4.26
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D06BB06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Penciclovir is an antiviral drug used for the topical treatment of herpes simplex virus (HSV) infections, primarily herpes labialis (cold sores) on the lips and face. It is a nucleoside analogue that inhibits viral DNA polymerase and is approved for topical use. Systemic administration is rare, and penciclovir is not commonly used orally or intravenously in clinical practice, as its prodrug famciclovir is preferred for systemic treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from published studies in healthy adult subjects after intravenous administration.</p><h4>References</h4><ol><li><p>Thomasy, SM, et al., &amp; Maggs, DJ (2012). Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. <i>American journal of veterinary research</i> 73(7) 1092–1099. DOI:<a href=\"https://doi.org/10.2460/ajvr.73.7.1092\">10.2460/ajvr.73.7.1092</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22738064/\">https://pubmed.ncbi.nlm.nih.gov/22738064</a></p></li><li><p>Gill, KS, &amp; Wood, MJ (1996). The clinical pharmacokinetics of famciclovir. <i>Clinical pharmacokinetics</i> 31(1) 1–8. DOI:<a href=\"https://doi.org/10.2165/00003088-199631010-00001\">10.2165/00003088-199631010-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8827396/\">https://pubmed.ncbi.nlm.nih.gov/8827396</a></p></li><li><p>Fowles, SE, et al., &amp; Staniforth, D (1992). The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. <i>European journal of clinical pharmacology</i> 43(5) 513–516. DOI:<a href=\"https://doi.org/10.1007/BF02285093\">10.1007/BF02285093</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1336464/\">https://pubmed.ncbi.nlm.nih.gov/1336464</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D06BB06;
